152 related articles for article (PubMed ID: 12743433)
1. Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor.
Baldi F; Malfertheiner P
Digestion; 2003; 67(1-2):1-5. PubMed ID: 12743433
[TBL] [Abstract][Full Text] [Related]
2. A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe.
Gremse DA; Donnelly JR; Kukulka MJ; Lloyd E; Lee C
Aliment Pharmacol Ther; 2004 Jun; 19(11):1211-5. PubMed ID: 15153174
[TBL] [Abstract][Full Text] [Related]
3. Formulation study for lansoprazole fast-disintegrating tablet. II. Effect of triethyl citrate on the quality of the products.
Shimizu T; Kameoka N; Iki H; Tabata T; Hamaguchi N; Igari Y
Chem Pharm Bull (Tokyo); 2003 Sep; 51(9):1029-35. PubMed ID: 12951443
[TBL] [Abstract][Full Text] [Related]
4. Formulation study for lansoprazole fast-disintegrating tablet. III. Design of rapidly disintegrating tablets.
Shimizu T; Sugaya M; Nakano Y; Izutsu D; Mizukami Y; Okochi K; Tabata T; Hamaguchi N; Igari Y
Chem Pharm Bull (Tokyo); 2003 Oct; 51(10):1121-7. PubMed ID: 14519914
[TBL] [Abstract][Full Text] [Related]
5. A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube.
Freston JW; Kukulka MJ; Lloyd E; Lee C
Aliment Pharmacol Ther; 2004 Aug; 20(4):407-11. PubMed ID: 15298634
[TBL] [Abstract][Full Text] [Related]
6. Formulation study for lansoprazole fast-disintegrating tablet. I. Effect of compression on dissolution behavior.
Shimizu T; Nakano Y; Morimoto S; Tabata T; Hamaguchi N; Igari Y
Chem Pharm Bull (Tokyo); 2003 Aug; 51(8):942-7. PubMed ID: 12913232
[TBL] [Abstract][Full Text] [Related]
7. An in vitro comparison of different providers to deliver four proton pump inhibitor products through a feeding tube.
Devlin JW; Bakshi A; Bungay K; Olsen KM
Aliment Pharmacol Ther; 2006 Dec; 24(11-12):1603-11. PubMed ID: 17206948
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects.
Freston JW; Chiu YL; Mulford DJ; Ballard ED
Aliment Pharmacol Ther; 2003 Feb; 17(3):361-7. PubMed ID: 12562448
[TBL] [Abstract][Full Text] [Related]
9. Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages.
Metz DC; Amer F; Hunt B; Vakily M; Kukulka MJ; Samra N
Aliment Pharmacol Ther; 2006 Apr; 23(7):985-95. PubMed ID: 16573801
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of fast disintegrating lansoprazole tablet in human subjects.
Iwasaki K; Yoshikawa Y; Shibata N; Takada K; Sakurai Y; Takagi N; Irie S; Nakamura K
Drug Metab Pharmacokinet; 2004 Jun; 19(3):227-35. PubMed ID: 15499190
[TBL] [Abstract][Full Text] [Related]
11. Effect of water intake on pharmacokinetics of lansoprazole from fast disintegrating tablet in human subjects.
Iwasaki K; Ito Y; Shibata N; Takada K; Sakurai Y; Takagi N; Irie S; Nakamura K
Drug Metab Pharmacokinet; 2004 Oct; 19(5):390-5. PubMed ID: 15548851
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor.
Freston JW
Am J Med; 2004 Sep; 117 Suppl 5A():14S-22S. PubMed ID: 15478848
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole.
Sharma VK
Am J Health Syst Pharm; 1999 Dec; 56(23 Suppl 4):S18-21. PubMed ID: 10597120
[TBL] [Abstract][Full Text] [Related]
14. Lansoprazole oro-dispersible tablet : pharmacokinetics and therapeutic use in acid-related disorders.
Baldi F
Drugs; 2005; 65(10):1419-26. PubMed ID: 15977971
[TBL] [Abstract][Full Text] [Related]
15. Clinical study on the pathophysiology and treatment of PPI-resistant ulcers.
Ashida K; Sakaguchi M; Tanaka M; Takiuchi H; Egashira Y; Katsu K
J Clin Gastroenterol; 1995; 20 Suppl 2():S67-71. PubMed ID: 7594345
[TBL] [Abstract][Full Text] [Related]
16. Lansoprazole: a proton pump inhibitor.
Garnett WR
Ann Pharmacother; 1996 Dec; 30(12):1425-36. PubMed ID: 8968456
[TBL] [Abstract][Full Text] [Related]
17. Uneven Distribution of Microgranules in Divided Lansoprazole Tablets.
Teitelbaum GA; Teitelbaum JE
J Pediatr Gastroenterol Nutr; 2015 Oct; 61(4):437-9. PubMed ID: 25885882
[TBL] [Abstract][Full Text] [Related]
18. [Usefulness of every-other day administration of proton pump inhibitors from the standpoint of continuous 48-hour pH measurements-- Comparison of cimetidine, omeprazole, and lansoprazole].
Yamamoto Y; Sezai S; Sakurabayashi S; Hirano M; Oka H
Nihon Shokakibyo Gakkai Zasshi; 1995 Jun; 92(6):919-24. PubMed ID: 7609313
[TBL] [Abstract][Full Text] [Related]
19. Which proton pump inhibitor should we use?
Williams CN
Can J Gastroenterol; 1997; 11(1):29. PubMed ID: 9113794
[No Abstract] [Full Text] [Related]
20. Pharmacokinetics and absolute bioavailability of lansoprazole.
Gerloff J; Mignot A; Barth H; Heintze K
Eur J Clin Pharmacol; 1996; 50(4):293-7. PubMed ID: 8803522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
